

# One-Fifth of Presenters Mum on Disclosures

BY JOYCE FRIEDEN

Despite explicit requirements, a number of speakers at medical meetings do not disclose financial conflicts of interest, a study has found.

"Currently, disclosures by physicians are largely self-reported, but there is reason to suspect that this may change in the near future," Dr. Kanu Okike of Brigham and Women's Hospital and Massachusetts General Hospital, in Boston, and colleagues wrote. "Legislation requiring all drug and device manufacturers to publicly disclose payments to physicians is currently pending in the U.S. Congress and has been met with widespread support."

The authors analyzed payments made to physicians in 2007 by five makers of total hip and knee prostheses that together account for nearly 95% of the market (N. Engl. J. Med. 2009;361:1466-74). They compared the payments with conflict of interest disclosures made by physicians who either presented at or served as board or committee members at the 2008 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).

A total of 1,347 payments were made to 1,162 physicians during 2007. Overall, 166 physicians received payments from multiple companies, and 282 payments exceeded \$100,000. One-fourth of the payments (344) were made to presenters or board/committee members at the AAOS meeting.

In 70% of the 299 cases that could be evaluated for topic relatedness, the payment was directly related to the topic of the presentation at the meeting.

The overall disclosure rate for the pay-

ments was 71%, including 79% for directly related payments, 50% for indirectly related payments, and 49% for unrelated payments. Of 91 surveyed physicians who did not disclose payments, 36 cited unrelated topics among their reasons.

The authors cited the high rate of nondisclosure as the most notable finding of their study, saying that the disclosures didn't occur "despite instructions directing each participant to make a disclosure

'if he or she has received something of value from a commercial company or institution, which relates directly or indirectly to the subject of their presentation.'"

They also noted that the 43 nondisclosed payments relating directly to the presentations totaled \$4.3 million.

Limitations of the study included assessing payment relatedness by comparing the presentation topic with the specialty of the companies in question,

which "could have underestimated the number of unrelated payments and, consequently, the overall rate of disclosure," they wrote.

As for their own disclosures, the authors noted that coauthors Dr. Mininder Kocher, Dr. Charles Mehlman, and Dr. Mohit Bhandari have received grants from or consulted for a number of medical device firms, including several of those mentioned in the study. ■

## INTUNIV™ (guanfacine) Extended-Release Tablets

### Rx Only

**BRIEF SUMMARY:** Consult the Full Prescribing Information for complete product information.

### INDICATIONS AND USAGE

INTUNIV™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of INTUNIV™ was studied for the treatment of ADHD in two controlled clinical trials (8 and 9 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV® criteria for ADHD (see *Clinical Studies in Full Prescribing Information*). The effectiveness of INTUNIV™ for longer-term use (more than 9 weeks) has not been systematically evaluated in controlled trials.

**Maintenance Treatment** The effectiveness of INTUNIV™ for longer-term use (more than 9 weeks) has not been systematically evaluated in controlled trials. Therefore the physician electing to use INTUNIV™ for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

### CONTRAINDICATIONS

Patients with a history of hypersensitivity to INTUNIV™, its inactive ingredients (see *Description in Full Prescribing Information*), or other products containing guanfacine (e.g. TENEX®) should not take INTUNIV™.

### WARNINGS AND PRECAUTIONS

**Hypotension, Bradycardia, and Syncope** Treatment with INTUNIV™ can cause decreases in blood pressure and heart rate. In the pediatric, short-term (8-9 weeks), controlled trials, the maximum mean changes from baseline in systolic blood pressure, diastolic blood pressure, and pulse were -5 mm Hg, -3 mm Hg, and -6 bpm, respectively, for all dose groups combined (generally one week after reaching target doses of 1 mg/day, 2 mg/day, 3 mg/day or 4 mg/day). These changes were dose dependent. Decreases in blood pressure and heart rate were usually modest and asymptomatic; however, hypotension and bradycardia can occur. Hypotension was reported as an adverse event for 6% of the INTUNIV™ group and 4% of the placebo group. Orthostatic hypotension was reported for 1% of the INTUNIV™ group and none in the placebo group. In long-term, open label studies, (mean exposure of approximately 10 months), maximum decreases in systolic and diastolic blood pressure occurred in the first month of therapy. Decreases were less pronounced over time. Syncope occurred in 1% of pediatric subjects in the clinical program. The majority of these cases occurred in the long-term, open-label studies. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Use INTUNIV™ with caution in patients with a history of hypotension, heart block, bradycardia, or cardiovascular disease, because it can decrease blood pressure and heart rate. Use caution in treating patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration. Use INTUNIV™ with caution in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope. Advise patients to avoid becoming dehydrated or overheated.

**Sedation and Somnolence** Somnolence and sedation were commonly reported adverse reactions in clinical studies (38% for INTUNIV™ vs. 12% for placebo) in children and adolescents with ADHD, especially during initial use (see *Adverse Reactions in Full Prescribing Information*). Before using INTUNIV™ with other centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines), consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with INTUNIV™. Advise patients to avoid use with alcohol.

**Other Guanfacine-Containing Products** Guanfacine, the active ingredient in INTUNIV™, is also approved as an antihypertensive. Do not use INTUNIV™ in patients concomitantly taking other guanfacine-containing products (e.g., Tenex).

### ADVERSE REACTIONS

**Clinical Trial Experience** Two short-term, placebo-controlled, double-blind pivotal studies (Studies 1 and 2) were conducted in children and adolescents with ADHD with a dose range of 1 to 4 mg/day of INTUNIV™. The most commonly reported adverse reactions (occurring in ≥2% of patients) that were considered drug-related and reported in a greater percentage of patients taking INTUNIV™ compared to patients taking placebo were: somnolence, headache, fatigue, upper abdominal pain, nausea, lethargy, dizziness, irritability, hypotension/decreased blood pressure, decreased appetite, dry mouth, and constipation. Less common adverse reactions (<2%) reported in pivotal Studies 1 and 2 that occurred in more than one patient taking INTUNIV™ and were more common than in the placebo group are atrioventricular block, bradycardia, sinus arrhythmia, dyspepsia, asthenia, chest pain, increased alanine aminotransferase, increased blood pressure, increased weight, postural dizziness, increased urinary frequency, enuresis, asthma, orthostatic hypotension, and pallor. In addition, the following less common (<2%) psychiatric disorders occurred in more than one patient receiving INTUNIV™ and were more common than in the placebo group. The relationship to INTUNIV™ could not be determined because these events may also occur as symptoms in pediatric patients

## INTUNIV™ (guanfacine) Extended-Release Tablets

with ADHD: agitation, anxiety, depression, emotional lability, nightmares or interrupted sleep. Twelve percent (12%) of patients receiving INTUNIV™ discontinued from the clinical studies due to adverse events, compared to 4% in the placebo group. The most common adverse reactions leading to discontinuation of INTUNIV™-treated patients from the studies were somnolence/sedation (6%) and fatigue (2%). Less common adverse reactions leading to discontinuation (occurring in approximately 1% of patients) included: hypotension/decreased blood pressure, headache, and dizziness. In the controlled long term studies (mean duration of approximately 10 months) with a dose range of 1 to 4 mg/day of INTUNIV™, the most common adverse reactions (≥5%) reported during open label treatment were somnolence, headache, fatigue, upper abdominal pain, hypotension/decreased blood pressure, vomiting, dizziness, nausea, weight increased, and irritability. The most frequent adverse reactions leading to discontinuation (≥2%) were somnolence (3%), syncopal events (2%), increased weight (2%), depression (2%), and fatigue (2%). Other adverse reactions leading to discontinuation in the long-term studies (occurring in approximately 1% of patients) included: hypotension/decreased blood pressure, sedation, headache, and lethargy. In long-term open label studies, serious adverse reactions occurring in more than one patient were syncope (2%) and convulsion (0.4%). Adverse reactions that occurred in <5% of patients but ≥2% in open-label, long-term studies that are considered possibly related to INTUNIV™ include: syncopal events, constipation, stomach discomfort, hypertension/increased blood pressure, decreased appetite, diarrhea, dry mouth, lethargy, and insomnia.

**Effects on Height, Weight, and Body Mass Index (BMI)** Patients taking INTUNIV™ demonstrated similar growth compared to normative data. Patients taking INTUNIV™ had a mean increase in weight of 1 kg (2 lbs) compared to those receiving placebo over a comparative treatment period. Patients receiving INTUNIV™ for at least 12 months in open-label studies gained an average of 8 kg (17 lbs) in weight and 8 cm (3 in) in height. The height, weight, and BMI percentile remained stable in patients at 12 months in the long-term studies compared to when they began receiving INTUNIV™.

**Laboratory Tests** In short and long-term studies, no clinically important effects were identified on any laboratory parameters.

**Effects on Heart Rate and QT Interval** The effect of two dose levels of immediate-release guanfacine (4 mg and 8 mg) on the QT interval was evaluated in a double-blind, randomized, placebo- and active-controlled, cross-over study in healthy adults. A dose-dependent decrease in heart rate was observed during the first 12 hours, at time of maximal concentrations. The mean change in heart rate was -13 bpm at 4 mg and -22 bpm at 8 mg. An apparent increase in mean QTc was observed for both doses. However, guanfacine does not appear to interfere with cardiac repolarization of the form associated with pro-arrhythmic drugs. This finding has no known clinical relevance.

### USE IN SPECIFIC POPULATIONS

**Pregnancy: Pregnancy Category B.** There are no adequate and well-controlled studies of guanfacine in pregnant women. This drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether guanfacine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when INTUNIV™ is administered to a nursing woman.

**Pediatric Use:** The safety and efficacy of INTUNIV™ in pediatric patients less than 6 years of age have not been established.

**Geriatric Use:** The safety and efficacy of INTUNIV™ in geriatric patients have not been established.

### DRUG ABUSE AND DEPENDENCE

INTUNIV™ is not a controlled substance and has no known potential for abuse or dependence.

### OVERDOSAGE

Two cases of accidental overdose of INTUNIV™ were reported in clinical trials in pediatric ADHD patients. These reports included adverse reactions of sedation and bradycardia in one patient and somnolence and dizziness in the other patient. Consult with a Certified Poison Control Center for up to date guidance and advice.

Manufactured for Shire US Inc., Wayne, PA 19087.

INTUNIV™ is a trademark of Shire LLC.

©2009 Shire Pharmaceuticals Inc.

August 2009 513 0207 001 INT-00239

## INDEX OF ADVERTISERS

<b>Abbott Nutrition</b>	
Pedialyte	33
<b>Alcon, Inc.</b>	
Vigamox	9-10
<b>Bausch &amp; Lomb Incorporated</b>	
Besivance	20-22
<b>DS Waters of America, Inc.</b>	
Nursery Water	15
<b>C.B. Fleet Company Inc.</b>	
Pedia-Lax	12
<b>Forest Laboratories, Inc.</b>	
Lexapro	27-31
AeroChamber Plus	10a-10b
<b>GlaxoSmithKline</b>	
Cervarix	3
<b>Merck &amp; Co., Inc.</b>	
RotaTeq	17-18
<b>Novartis Pharmaceuticals Corporation</b>	
Corporate	7
Menveo	23
<b>Pfizer Inc.</b>	
Zmax	4-6
<b>Shire US Inc.</b>	
Intuniv	18a-18d, 35-36
<b>Sanofi Pasteur Inc.</b>	
Adacel	13-14
<b>Unilever</b>	
Dove	25
<b>Wyeth Consumer Healthcare</b>	
Dimetapp	16